Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Gilead ( GILD) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.8%. By the end of trading, Gilead fell $0.80 (-1.3%) to $60.95 on light volume. Throughout the day, 6,058,818 shares of Gilead exchanged hands as compared to its average daily volume of 10,905,000 shares. The stock ranged in price between $60.43-$61.90 after having opened the day at $61.75 as compared to the previous trading day's close of $61.75. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 40.0%, Prima Biomed ( PBMD), down 8.8%, Prosensa Holding N.V ( RNA), down 8.2% and Chembio Diagnostics ( CEMI), down 7.5%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $94.6 billion and is part of the health care sector. Shares are up 68.8% year to date as of the close of trading on Friday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, increase in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Compugen ( CGEN), up 44.5%, Inovio Pharmaceuticals ( INO), up 44.2%, Aastrom Biosciences ( ASTM), up 31.1% and Onconova Therapeutics ( ONTX), up 23.8% , were all gainers within the drugs industry with Illumina ( ILMN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside